Tylenol Autism Lawsuit: What the 2026 Court Ruling Means for Families

●       On July 13, 2026, the U.S. Court of Appeals for the Second Circuit revived more than 500 Tylenol autism lawsuits, reversing a lower-court ruling that had effectively ended the federal case.

●       The federal litigation is consolidated as In re: Acetaminophen ASD-ADHD Products Liability Litigation, MDL No. 1:22-md-3043, before U.S. District Judge Denise L. Cote in the Southern District of New York.

●       The appeals court ruled only on whether plaintiffs' expert witnesses can testify, not on whether acetaminophen actually causes autism or ADHD; that question is still unresolved.

●       No Tylenol autism settlement exists as of July 2026. No compensation amounts, payout ranges, or claim deadlines have been publicly established.

●       Texas Attorney General Ken Paxton filed a separate state lawsuit against Johnson & Johnson and Kenvue in October 2025, and additional state-court cases have been filed in Pennsylvania, Florida, and Illinois in 2026.

●       Kenvue, the FDA, and major medical groups including ACOG maintain there is no confirmed causal link, while the Trump administration and some researchers argue the association warrants a warning label.

 

A Tylenol autism lawsuit is a legal claim alleging that a manufacturer or retailer failed to warn pregnant women that acetaminophen, the active ingredient in Tylenol, might increase a child's risk of autism spectrum disorder (ASD) or ADHD. As of July 2026, more than 500 of these cases were revived by a federal appeals court after being dismissed in 2024. No settlement exists yet, and no court has ruled that Tylenol causes autism.

The Tylenol autism lawsuit refers to a group of product liability cases claiming that Johnson & Johnson, its consumer health spinoff Kenvue Inc., and major retailers sold acetaminophen products without adequately warning that prenatal exposure might be linked to neurodevelopmental disorders. Plaintiffs include parents who used Tylenol or generic acetaminophen while pregnant and later had a child diagnosed with autism or ADHD.

Named defendants across the litigation include Kenvue, Johnson & Johnson, and retailers such as CVS, Costco, Kroger, Rite Aid, Safeway, Sam's Club, Target, Walgreens, and Walmart, which sold store-brand acetaminophen. The claims rely on failure-to-warn and, in Texas's case, deceptive marketing theories rather than a manufacturing defect.

On July 13, 2026, a three-judge panel of the U.S. Court of Appeals for the Second Circuit unanimously reversed a lower-court ruling and revived more than 500 Tylenol acetaminophen autism lawsuits that had been dismissed in 2024. The panel returned the cases to U.S. District Judge Denise L. Cote in the Southern District of New York for further proceedings.

The appeals court reinstated three of the five plaintiff experts previously excluded: Dr. Andrea Baccarelli, dean of the Harvard T.H. Chan School of Public Health; Dr. Eric Hollander, a psychiatry professor at Albert Einstein College of Medicine; and Dr. Brandon Pearson, a toxicologist at Columbia University. Two experts, Drs. Cabrera and Louie, remain excluded.

The table below lays out the confirmed procedural history of the federal Tylenol acetaminophen autism lawsuit, drawn from court filings and official statements, current as of July 22, 2026.

As of July 22, 2026, the federal Tylenol autism lawsuit is captioned In re: Acetaminophen ASD-ADHD Products Liability Litigation, MDL No. 1:22-md-3043 (DLC), pending in the U.S. District Court for the Southern District of New York before Judge Denise L. Cote, with Magistrate Judge Katharine H. Parker handling settlement referrals. Following the Second Circuit's July 13, 2026 decision, the more than 500 revived cases are back before Judge Cote for renewed proceedings on expert admissibility and, eventually, case-specific evidence.

By mid-2024, before the dismissal, court trackers reported roughly 321 active cases pending in the MDL; that figure has since grown as revived and newly filed cases are added. Kenvue's own securities filings acknowledge that many federal claims were dismissed but are being appealed, consistent with the July 2026 outcome. Exact current case counts have not been published by the court as of this writing.

No trial date has been set. Judge Cote is expected to set a new case-management schedule addressing outstanding discovery, additional Daubert proceedings for the two still-excluded experts, and the eventual selection of representative cases for bellwether trials, a process where a small number of cases are tried first to help gauge how juries might view similar claims.

No. As of July 22, 2026, there is no confirmed Tylenol autism settlement, settlement fund, or compensation program. No dollar figures, payout ranges, or claim-filing deadlines have been announced by any court, defendant, or plaintiffs' steering committee. Any website, ad, or caller promising a guaranteed payout amount is not describing an actual resolved case.

Because the July 2026 ruling addressed only expert admissibility, and not causation, a global settlement is not considered likely in the near term. Settlement talks typically intensify only after causation and liability issues are further resolved, through additional court rulings or early bellwether trial verdicts.

Yes. Not every Tylenol pregnancy autism lawsuit is part of the federal MDL. Some families and one state government have filed separate claims in state court.

On October 28, 2025, Texas Attorney General Ken Paxton filed a lawsuit against Johnson & Johnson and Kenvue in the District Court of Panola County, Texas. The suit alleges the companies violated the Texas Deceptive Trade Practices-Consumer Protection Act by marketing Tylenol as the only safe pain reliever for pregnant women while allegedly concealing research on possible neurodevelopmental risks.

The state is seeking a jury trial, civil penalties of $10,000 per violation, an order requiring the companies to destroy marketing materials describing Tylenol as safe for pregnant women and children, and injunctive relief. On February 26, 2026, a Texas judge denied the defendants' motion to dismiss the case, allowing it to proceed. Kenvue has stated it will "vigorously defend" itself and says it stands with "the global medical community" on the drug's safety.

Beginning in March 2026, additional individual and family lawsuits alleging acetaminophen-linked autism or ADHD were filed in state courts in Pennsylvania, Florida, and Illinois, separate from the federal MDL. These cases proceed on their own schedules under each state's law and are not automatically affected by rulings in the New York federal case.

On September 22, 2025, President Trump, HHS Secretary Robert F. Kennedy Jr., and then-FDA Commissioner Dr. Marty Makary announced that the FDA would issue a notice to physicians and begin a process to update acetaminophen's safety label to reference a possible association with autism and ADHD when used during pregnancy. Officials cited a research review, published in BMC Environmental Health on August 14, 2025 by Dr. Andrea Baccarelli and colleagues, that reported an association between prenatal acetaminophen exposure and neurodevelopmental disorders using a methodology called the Navigation Guide.

As of this writing, the FDA has not finalized a label change. Kenvue formally petitioned the FDA on October 17, 2025 to reject the proposed warning, arguing it is "unsupported by the scientific evidence and legally and procedurally improper." The FDA's own acetaminophen safety page, last updated in August 2025, stated the agency "has not found clear evidence that appropriate use of acetaminophen during pregnancy causes adverse pregnancy, birth, neurobehavioral, or developmental outcomes," according to CNN's review of the page in October 2025. The American College of Obstetricians and Gynecologists (ACOG) has separately reaffirmed acetaminophen's safety profile for pregnant patients.

The underlying science remains genuinely contested. A 2020 JAMA Psychiatry study and the 2025 Baccarelli review both reported associations between prenatal acetaminophen exposure and ASD or ADHD risk. A separate 2024 JAMA study, cited by health-policy outlet AJMC, found no causal link. Because the studies are observational, researchers on both sides caution that they show correlation, not proof that acetaminophen causes these conditions. Readers should treat any specific percentage increase in risk cited by advocacy groups or law firms as disputed and unconfirmed by the FDA.

You may be part of the group potentially affected by this litigation if:

●       You took Tylenol or a generic/store-brand acetaminophen product regularly during pregnancy, and

●       Your child was later diagnosed with autism spectrum disorder, ADHD, or a related neurodevelopmental condition, and

●       You believe you were not adequately warned of a possible risk at the time you used the product.

Meeting these general criteria does not guarantee eligibility to file a claim or entitlement to any Tylenol autism compensation claim. Eligibility depends on factors such as your state's statute of limitations (the legal deadline to file suit), the strength of medical documentation connecting exposure and diagnosis, and how the underlying causation science develops as the litigation proceeds. This section is general information, not personalized legal advice.

If you believe you or your family may have a Tylenol autism legal case, consider the following general steps. This is educational information only and not a substitute for advice from a licensed attorney about your specific situation.

1.      Gather documentation. Collect medical records showing acetaminophen use during pregnancy (prescriptions, pharmacy records, or provider notes) and your child's diagnostic records for ASD or ADHD.

2.      Note your timeline. Write down when and how often you used Tylenol or a generic acetaminophen product during pregnancy, and when your child was diagnosed.

3.      Check your state's filing deadline. Statutes of limitations for product liability claims vary by state and can be affected by when a diagnosis occurred or was discovered, so timing matters.

4.      Consult a qualified attorney. Product liability and mass tort attorneys, including those experienced with multidistrict litigation, can evaluate whether your situation may support a claim and explain your options at no upfront cost in many cases.

5.      Be skeptical of guaranteed outcomes. Because no settlement exists, be wary of any advertisement, intake call, or website promising a specific payout amount or guaranteed compensation.

You can also review official docket information for MDL No. 1:22-md-3043 through the Southern District of New York's website, or file a general product complaint with the FDA's MedWatch program if you experienced an adverse event you believe is drug-related.

How Do I Find Tylenol Autism Lawsuit Attorneys?

Tylenol Autism Lawsuit Update: Current Status as of July 22, 2026

Yes. As of July 2026, the federal MDL is active again after the Second Circuit revived more than 500 previously dismissed cases on July 13, 2026. A separate Texas state lawsuit against Johnson & Johnson and Kenvue is also proceeding after a judge declined to dismiss it in February 2026.

No. As of July 22, 2026, no plaintiff has won a Tylenol autism lawsuit at trial, and no class-wide or individual settlement has been publicly confirmed. The July 2026 ruling only allows certain expert testimony to be heard; it does not decide whether Tylenol causes autism or award any compensation.

This has not been proven in court or established as scientific consensus. Some observational studies, including a 2020 JAMA Psychiatry study and a 2025 review led by Dr. Andrea Baccarelli, report an association between prenatal acetaminophen use and autism or ADHD risk. Other research, including a 2024 JAMA study, found no causal link. The FDA has not concluded that acetaminophen causes these conditions, and Kenvue disputes the claim.

Generally, parents who used Tylenol or generic acetaminophen during pregnancy and later had a child diagnosed with autism spectrum disorder or ADHD may be able to explore a claim, subject to their state's filing deadlines and the strength of their documentation. An attorney can evaluate individual eligibility; this is not a guarantee that any specific person qualifies.

No compensation amounts can be accurately quoted. Because no settlement or trial verdict exists as of July 2026, any specific dollar figure you see online for a Tylenol autism compensation claim is speculative and not based on a confirmed case outcome.

MDL No. 1:22-md-3043, formally In re: Acetaminophen ASD-ADHD Products Liability Litigation, is the federal multidistrict litigation that consolidates Tylenol autism and ADHD lawsuits from around the country before a single judge, Denise L. Cote, in the Southern District of New York, for coordinated pretrial proceedings.

The Southern District of New York publishes docket information and selected orders for MDL No. 1:22-md-3043 on its website. A PACER account is required to view full case dockets. A licensed attorney can also confirm the current status of a specific claim.